Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 13/20 | 0.42 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12539935 | 0.85 | GRM4 (0.38) | DAOCCNKCDK12ALDH1A1KDM4E | |
| SCHEMBL30615518 | 0.75 | DAO (0.53) | DAOPRKCQPRKCAALDH1A1FEN1 | |
| SCHEMBL21467334 | 0.75 | DAO (0.53) | DAOPRKCQPRKCAALDH1A1FEN1 | |
| SCHEMBL11511885 | 0.74 | DAO (0.58) | DAOPRKCQPRKCAALDH1A1HSD17B10 | |
| SCHEMBL12539936 | 0.73 | TNKS2 (0.34) | CCNKCDK12ALDH1A1KDM4E | |
| SCHEMBL13933686 | 0.73 | DAO (0.57) | DAOPRKCQPRKCAALDH1A1FEN1 | |
| SCHEMBL30615330 | 0.72 | DAO (0.49) | DAOPRKCQPRKCAALDH1A1KDM4E | |
| SCHEMBL21463501 | 0.72 | DAO (0.49) | DAOPRKCQPRKCAALDH1A1KDM4E | |
| SCHEMBL30257859 | 0.72 | DAO (0.55) | DAOPRKCQPRKCAALDH1A1FEN1 | |
| SCHEMBL30794441 | 0.70 | DAO (0.53) | DAOPRKCQPRKCAALDH1A1FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946257-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | VECTURA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | PALAU PHARMA, S.A. | 2013-10-31 | — | — | US | disclosed |
| US-8501735-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | PALAU PHARMA, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| US-20130131038-A9 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | VECTURA LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20120245140-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | ALMANSA ROSALES CARMEN (ES) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | DAO 774/4885PRKCQ 570/4885CCNK 465/4885 |
| US-20120245140-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | DAO 774/4885PRKCQ 570/4885CCNK 465/4885 |
| US-20130131038-A9 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | DAO 774/4885PRKCQ 570/4885CCNK 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.